Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$16.35 - $27.5 $2.41 Million - $4.06 Million
147,632 Added 48.78%
450,251 $9.95 Million
Q1 2022

May 16, 2022

BUY
$15.98 - $19.65 $921,950 - $1.13 Million
57,694 Added 23.56%
302,619 $5.66 Million
Q3 2021

Nov 15, 2021

SELL
$13.14 - $20.97 $3.9 Million - $6.22 Million
-296,638 Reduced 54.77%
244,925 $4.23 Million
Q2 2021

Aug 16, 2021

BUY
$18.05 - $29.59 $750,212 - $1.23 Million
41,563 Added 8.31%
541,563 $9.84 Million
Q1 2021

May 14, 2021

BUY
$25.25 - $40.11 $12.6 Million - $20.1 Million
500,000 New
500,000 $14 Million

Others Institutions Holding PHVS

About Pharvaris N.V.


  • Ticker PHVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,766,000
  • Market Cap $625M
  • Description
  • Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...
More about PHVS
Track This Portfolio

Track Eventide Asset Management, LLC Portfolio

Follow Eventide Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eventide Asset Management, LLC with notifications on news.